Stephen W. Harbin Net Worth

The estimated Net Worth of Stephen Harbin is at least $817 mil dollars as of 16 November 2021. Mr Harbin owns over 30,000 units of Oncorus stock worth over $1,808 and over the last 4 years he sold ONCR stock worth over $0. In addition, he makes $815,088 as COO & Chief of Staff at Oncorus.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Harbin ONCR stock SEC Form 4 insiders trading

Mr has made over 1 trades of the Oncorus stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 30,000 units of ONCR stock worth $173,700 on 16 November 2021.

The largest trade he's ever made was buying 30,000 units of Oncorus stock on 16 November 2021 worth over $173,700. On average, Mr trades about 6,000 units every 0 days since 2020. As of 16 November 2021 he still owns at least 15,000 units of Oncorus stock.

You can see the complete history of Mr Harbin stock trades at the bottom of the page.

Mr. Stephen W. Harbin biography

Stephen W. Harbin is the COO & Chief of Staff at Oncorus.

What is the salary of Mr Harbin?

As the COO & Chief of Staff of Oncorus, the total compensation of Mr Harbin at Oncorus is $815,088. There are no executives at Oncorus getting paid more.

How old is Mr Harbin?

Mr Harbin is 62, he's been the COO & Chief of Staff of Oncorus since . There are no older and 8 younger executives at Oncorus.

What's Mr Harbin's mailing address?

Stephen's mailing address filed with the SEC is C/O ONCORUS, INC., 4 CORPORATE DRIVE, ANDOVER, MA, 01810.

Insiders trading at Oncorus

Over the last 4 years, insiders at Oncorus have traded over $1,276,271 worth of Oncorus stock and bought 2,354,001 units worth $35,555,648 . The most active insiders traders include Ansbert Gadicke, Luke Evnin y James E Deerfield Mgmt Hif,.... On average, Oncorus executives and independent directors trade stock every 34 days with the average trade being worth of $15,538. The most recent stock trade was executed by James E Deerfield Mgmt Hif,... on 28 December 2022, trading 336,235 units of ONCR stock currently worth $87,421.

What does Oncorus do?

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Complete history of Mr Harbin stock trades at Oncorus

Oncorus executives and stock owners

Oncorus executives and other stock owners filed with the SEC include:

• Stephen W. Harbin,
  COO & Chief of Staff
• Dr. Theodore T. Ashburn M.D., Ph.D.,
  Pres, CEO & Director
• Dr. Theodore T. Ashburn,
  Pres, CEO & Director
• Dr. Christophe Queva Ph.D.,
  Chief Scientific Officer & Sr. VP of Research
• Stephen Harbin,
  COO & Chief of Staff
• Dr. Mitchell H. Finer Ph.D.,
  Co-Founder & Non-Exec. Chairman
• Dr. Mitchell H. Finer,
  Co-Founder & Exec. Chairman
• Chris German,
  Controller
• Brian J. Shea,
  Director of Legal Counsel & Corp. Sec.
• Richard J. Wanstall M.B.A.,
  CFO, Chief Accounting Officer & Treasurer
• Dr. John Mayer Goldberg M.D.,
  Sr. VP of Clinical Devel.
• John McCabe M.B.A.,
  CFO, Treasurer & Sec.
• Scott A Canute,
  Director
• Rick Wanstall,
  CFO and Treasurer
• Theodore Ashburn,
  President and CEO
• Christophe Queva,
  CSO and SVP, Research
• James E Deerfield Mgmt Hif,...,
  
• Luke Evnin,
  Director
• Oncology Impact Fund L.P.On...,
  
• Ansbert Gadicke,
  10% owner
• Mitchell H. Finer,
  Director
• Bio Ventures 2014, L.P.Fole...,
  
• Spencer Nam,
  Director
• Sun States Fund, L.P.Mpm As...,
  
• Stephen Harbin,
  COO and Chief of Staff
• John P. Mc Cabe,
  CFO and Treasurer
• Mary Kay Fenton,
  Director
• Eric Rubin,
  Director
• Barbara Yanni,
  Director
• John Mayer Goldberg,
  Chief Medical Officer
• James E Deerfield Mgmt Hif,...,
  
• Douglas Fambrough,
  Director